Intervacc AB (publ) (IVACC.ST)
SEK 0.94
(-0.74%)
SEK 0.94
(-0.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 259.61 Million SEK | -2.05% |
| 2022 | 265.03 Million SEK | -19.54% |
| 2021 | 329.39 Million SEK | -7.29% |
| 2020 | 355.28 Million SEK | 49.87% |
| 2019 | 237.06 Million SEK | 16.98% |
| 2018 | 202.66 Million SEK | 12.81% |
| 2017 | 179.64 Million SEK | 9.77% |
| 2016 | 163.65 Million SEK | 5.62% |
| 2015 | 154.95 Million SEK | 0.03% |
| 2014 | 154.91 Million SEK | 194.33% |
| 2013 | 52.63 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 226.52 Million SEK | -5.16% |
| 2024 Q1 | 238.84 Million SEK | -8.0% |
| 2023 Q2 | 324.95 Million SEK | 29.48% |
| 2023 FY | 259.61 Million SEK | -2.05% |
| 2023 Q4 | 259.61 Million SEK | -5.97% |
| 2023 Q1 | 250.97 Million SEK | -5.31% |
| 2023 Q3 | 276.1 Million SEK | -15.03% |
| 2022 Q3 | 294.89 Million SEK | -3.0% |
| 2022 Q1 | 316.26 Million SEK | -3.99% |
| 2022 FY | 265.03 Million SEK | -19.54% |
| 2022 Q2 | 304.01 Million SEK | -3.87% |
| 2022 Q4 | 265.03 Million SEK | -10.13% |
| 2021 FY | 329.39 Million SEK | -7.29% |
| 2021 Q1 | 343.97 Million SEK | -3.18% |
| 2021 Q4 | 329.39 Million SEK | -1.27% |
| 2021 Q3 | 333.63 Million SEK | -2.15% |
| 2021 Q2 | 340.97 Million SEK | -0.87% |
| 2020 Q2 | 367.6 Million SEK | 60.76% |
| 2020 Q1 | 228.66 Million SEK | -3.55% |
| 2020 Q3 | 360.59 Million SEK | -1.91% |
| 2020 FY | 355.28 Million SEK | 49.87% |
| 2020 Q4 | 355.28 Million SEK | -1.47% |
| 2019 FY | 237.06 Million SEK | 16.98% |
| 2019 Q2 | 192.57 Million SEK | -0.63% |
| 2019 Q4 | 237.06 Million SEK | -2.65% |
| 2019 Q3 | 243.52 Million SEK | 26.45% |
| 2019 Q1 | 193.79 Million SEK | -4.37% |
| 2018 Q2 | 221.41 Million SEK | 30.57% |
| 2018 FY | 202.66 Million SEK | 12.81% |
| 2018 Q4 | 202.66 Million SEK | -3.37% |
| 2018 Q3 | 209.73 Million SEK | -5.27% |
| 2018 Q1 | 169.57 Million SEK | -5.61% |
| 2017 Q3 | 184.53 Million SEK | -12.25% |
| 2017 Q4 | 179.64 Million SEK | -2.65% |
| 2017 FY | 179.64 Million SEK | 9.77% |
| 2017 Q1 | 208.81 Million SEK | 27.59% |
| 2017 Q2 | 210.3 Million SEK | 0.72% |
| 2016 Q4 | 163.65 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | 163.65 Million SEK | 5.62% |
| 2015 FY | 154.95 Million SEK | 0.03% |
| 2014 FY | 154.91 Million SEK | 194.33% |
| 2013 FY | 52.63 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Isofol Medical AB (publ) | 140.59 Million SEK | -84.649% |
| Kancera AB (publ) | 65.64 Million SEK | -295.489% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -1195.399% |
| Xintela AB (publ) | 18.39 Million SEK | -1311.313% |
| AcouSort AB (publ) | 34.51 Million SEK | -652.212% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -19.615% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 6.864% |
| NextCell Pharma AB | 81.28 Million SEK | -219.372% |
| Amniotics AB (publ) | 26.08 Million SEK | -895.212% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -1645.988% |
| Simris Alg AB (publ) | 174.55 Million SEK | -48.73% |
| Active Biotech AB (publ) | 44 Million SEK | -490.025% |
| Alzinova AB (publ) | 123.18 Million SEK | -110.742% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -4172.026% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -119.173% |
| BioArctic AB (publ) | 1.18 Billion SEK | 78.112% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 86.34% |
| Camurus AB (publ) | 1.9 Billion SEK | 86.392% |
| Cantargia AB (publ) | 223.71 Million SEK | -16.047% |
| CombiGene AB (publ) | 120.61 Million SEK | -115.245% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -760.407% |
| Genovis AB (publ.) | 288.85 Million SEK | 10.125% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -204.611% |
| Mendus AB (publ) | 755.95 Million SEK | 65.658% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 79.37% |
| LIDDS AB (publ) | 17.65 Million SEK | -1370.467% |
| Lipum AB (publ) | 12.11 Million SEK | -2043.774% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -672.606% |
| OncoZenge AB (publ) | 20.34 Million SEK | -1176.357% |
| Saniona AB (publ) | 64.14 Million SEK | -304.738% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -389.971% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -1096.206% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 47.685% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 60.274% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 66.076% |
| Ziccum AB (publ) | 14.97 Million SEK | -1633.977% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -316.197% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -518.725% |
| Corline Biomedical AB | 100.1 Million SEK | -159.339% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -46.573% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -317.703% |
| Aptahem AB (publ) | 63.02 Million SEK | -311.918% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 26.107% |
| Fluicell AB (publ) | 9.34 Million SEK | -2679.561% |
| Biovica International AB (publ) | 131.4 Million SEK | -97.561% |
| Abliva AB (publ) | 87.49 Million SEK | -196.702% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 65.85% |
| 2cureX AB (publ) | 16.62 Million SEK | -1461.57% |
| I-Tech AB | 152.44 Million SEK | -70.3% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 74.499% |
| Cyxone AB (publ) | 43.65 Million SEK | -494.688% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -229.908% |
| Biosergen AB | 7.2 Million SEK | -3505.208% |
| Nanologica AB (publ) | 77.42 Million SEK | -235.289% |
| SynAct Pharma AB | 228.01 Million SEK | -13.855% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -870.037% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 81.459% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -8.907% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -2970.503% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -198.157% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -810.66% |